FINACEA Drug Patent Profile

« Back to Dashboard

When do Finacea patents expire, and when can generic versions of Finacea launch?

Finacea is a drug marketed by Leo Pharma As and is included in two NDAs. There are four patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in FINACEA is azelaic acid. There is one drug master file entry for this compound. Eight suppliers are listed for this compound. Additional details are available on the azelaic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Finacea

A generic version of FINACEA was approved as azelaic acid by ACTAVIS LABS UT INC on November 19^th, 2018.

Summary for FINACEA

US Patents:	4
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	116
Clinical Trials:	12
Patent Applications:	3,656
Drug Prices:	Drug price information for FINACEA
Drug Sales Revenues:	Drug sales revenues for FINACEA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FINACEA
What excipients (inactive ingredients) are in FINACEA?	FINACEA excipients list
DailyMed Link:	FINACEA at DailyMed

See drug prices for FINACEA

See drug sales revenues for FINACEA

Recent Clinical Trials for FINACEA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wake Forest University Health Sciences	Early Phase 1
Clinical Research Center of the Carolinas	Phase 4
DPT Laboratories, Ltd.	Phase 3

See all FINACEA clinical trials

Pharmacology for FINACEA

Physiological Effect

Decreased Protein Synthesis Decreased Sebaceous Gland Activity

Paragraph IV (Patent) Challenges for FINACEA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FINACEA	Topical Foam	azelaic acid	15%	207071	1	2017-09-14
FINACEA	Gel	azelaic acid	15%	021470	1	2012-07-27

US Patents and Regulatory Information for FINACEA

FINACEA is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes			Y
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes			Y
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes			Y
Leo Pharma As	FINACEA	azelaic acid	GEL;TOPICAL	021470-001	Dec 24, 2002	AB	RX	Yes	Yes

Expired US Patents for FINACEA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Leo Pharma As	FINACEA	azelaic acid	GEL;TOPICAL	021470-001	Dec 24, 2002
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015
Leo Pharma As	FINACEA	azelaic acid	GEL;TOPICAL	021470-001	Dec 24, 2002
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015

International Patents for FINACEA

When does loss-of-exclusivity occur for FINACEA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FINACEA around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	229654
Germany	3750934
Germany	3751780
European Patent Office	0229654	Traitement des dermatoses inflammatoires et infectieuses diffèrentes de l'acné et de la chute des cheveux. (Treatment of non-acne inflammatory and infectious dermatoses.)
European Patent Office	0593093	Traitement de chute de cheveux (Treatment of hair loss)
Japan	2505983
Japan	H07309751	REMEDY FOR INFLAMMATORY OR HORMONAL ALOPECIA

Last updated: July 20, 2026

FINACEA (azelaic acid 15% foam): Market dynamics, pricing trends, and financial trajectory

FINACEA (azelaic acid 15% foam), marketed in the U.S. for mild-to-moderate inflammatory acne, faces a low-value niche profile in branded dermatology. Sales are constrained by (1) limited penetration versus oral acne standards, (2) competition from inexpensive topical retinoids and antibiotics, (3) the inherently modest reimbursement economics of topical acne products, and (4) exposure to generic substitution risk in the azelaic-acid space once ANDA-relevant exclusivities and listed patents expire. Near-term brand growth depends more on payer formulary placement and adherence-driven dosing than on clinically differentiated endpoints.

How is FINACEA performing in the acne market and what drives demand?

Core demand drivers (U.S.)

• Indication positioning: mild-to-moderate inflammatory acne; use case is typically add-on to baseline skincare or as a standalone topical for patients seeking non-antibiotic options.
• Patient adherence: twice-daily topical regimens are adherence-sensitive; foam delivery can improve spread and tolerability versus some older vehicles, but real-world persistence drives volume.
• Payer and formulary access: branded topical acne products generally compete against low-cost generics on tiering. When FINACEA is excluded or placed on a high copay tier, patient acquisition slows sharply.

Market structure

• Acne treatment market economics tilt to low acquisition cost (generics) and formulary incumbency.
• Branded topicals often capture share when they offer a tolerability or convenience advantage paired with manufacturer rebate strategy, not on large clinical superiority.

Competitor set that shapes utilization

• OTC and generic topicals: benzoyl peroxide, adapalene, tretinoin, topical clindamycin combinations where permitted by stewardship policies.
• Branded topical acne brands: typically defend on vehicle tolerability, patient education support, and payer contracting rather than on exclusivity length.

What is the historical pricing and reimbursement profile for FINACEA?

Pricing pressure profile

• Topical acne products face recurring downward pricing pressure because payers anchor to generic comparators and negotiate rebates for branded products.
• Foam formulations in dermatology tend to land at premium ASPs relative to creams and gels; however, pharmacy reimbursement often converges toward net prices after rebates.

Reimbursement realities

• For niche branded dermatology, net price is the market-relevant metric: gross list pricing rarely predicts realized revenue.
• Tier placement affects patient starts more than clinical labeling breadth.

Where does FINACEA’s financial trajectory come from: launches, share, and channel mix?

Trajectory mechanics for a branded topical

1. Launch ramp: early sales are shaped by dermatology and primary-care prescribing behavior plus pharmacy access.
2. Mid-period stabilization: demand becomes payer-driven. If formularies tighten, brand prescription volume flattens.
3. Late-cycle erosion risk: generic azelaic acid products or vehicle-specific ANDAs can pressure market share and net price once patent and exclusivity barriers clear.

Channel mix

• Dermatology clinic prescribing tends to drive initial adoption.
• Pharmacy fill behavior depends on coverage and prior authorization requirements, if any.

Which patent and exclusivity events can move FINACEA revenue up or down?

Key market-influencing IP events

• Orange Book-listed patents and related FDA exclusivity windows determine whether ANDA entry is feasible without infringement exposure.
• For acne topicals, even a small share loss can materially impact a small brand’s revenue line because fixed costs (medical affairs, market access, distribution) do not scale down proportionally.

Practical financial impact

• When patent-protected branded topicals lose exclusivity, revenue typically declines via a combination of:
  • prescription switching to generics,
  • net price compression from increased payer competition, and
  • marketing spend reallocation by the brand owner.

What does the Orange Book status of FINACEA indicate about generic entry risk?

Orange Book implications

• If FINACEA has limited remaining listed patents with enforceable expiration dates, ANDA paragraph IV risk rises as the “runway” shrinks.
• If formulation- or method-of-use patents are present and enforceable, generic entry is slowed but not eliminated if generic challenges narrow to carve-outs or design-arounds.

Generic entry risk profile

• Azelaic acid has a history of being available as generics in some forms and strengths. The financial threat is not only “a generic azelaic acid product,” but “a product positioned as therapeutically equivalent with comparable vehicle and dosing convenience.”

When does FINACEA lose exclusivity and what are the typical effects on sales?

Sales effect pattern

• In topical dermatology, post-exclusivity declines are often sharp in the first 6 to 12 months as pharmacies switch to lower-cost products under payer guidance.
• The magnitude depends on:
  • the number of generic entrants,
  • whether generics match the foam vehicle and dosing regimen closely,
  • and whether the brand owner maintains formulary access through rebates and contracting.

Timing sensitivity

• Final-year revenue is disproportionately affected by “patient harvesting” behavior: payers and patients reposition before patent cliffs to reduce cost exposure.

How do legal and Paragraph IV challenges affect FINACEA’s market access and revenue?

Paragraph IV litigation channels

• Filing of ANDAs with paragraph IV certifications can trigger:
  • automatic 30-month stay (if statutory conditions are met),
  • settlement that delays launch,
  • or accelerated generic entry if the stay does not apply or litigation ends quickly.

Revenue mechanisms

• Litigation and settlement outcomes affect:
  • the expected date of generic substitution,
  • payer negotiation leverage,
  • and brand owner willingness to discount.

What formulation patents might protect FINACEA beyond the active ingredient?

Patent categories that protect brands in topicals

• Vehicle and foam composition patents (stabilizers, surfactants, propellants or gas systems where relevant, rheology control).
• Method-of-manufacture patents (process steps that control foam uniformity and stability).
• Formulation particle-size and stability claims that drive bioavailability and tolerability.

Why formulation IP matters financially

• Generic designers can sometimes avoid active-ingredient patent claims by copying the active compound but cannot always match foam performance without risking infringement.
• If formulation patents remain enforceable late in the lifecycle, brand switching can slow until a credible design-around exists.

How does FINACEA compare with competing acne topicals on differentiation and commercial defensibility?

Differentiation axes

• Vehicle tolerance: foam can reduce irritation relative to some creams, which helps adherence.
• Patient experience: ease of application and reduced mess can improve persistence.
• Non-antibiotic profile: supports prescribing in stewardship contexts where clinicians prefer to reduce antibiotic reliance.

Commercial defensibility

• Defensibility usually depends on whether payers perceive a meaningful net-cost offset, such as fewer discontinuations or better outcomes that prevent escalation.
• In many acne portfolios, clinical differentiation is not sufficient to overcome generic price competition without favorable formulary terms.

What biosimilar or biologics dynamics matter for FINACEA?

Biosimilar relevance

• FINACEA is a small-molecule topical azelaic acid product. Biosimilar frameworks do not apply.

What manufacturing and supply-chain/IP barriers could affect future generic competition?

Barriers that often matter for topical generics

• Demonstrating foam stability, consistent dosing, and performance specs.
• Manufacturing process validation to meet NDA/ANDA equivalence requirements.
• Quality control and packaging specs that replicate dose delivery from foam canisters/dispensing systems.

Regional expansion and geographic revenue exposure: where does FINACEA’s growth come from?

U.S.-centric economics

• Most financial trajectory in branded acne topicals is U.S.-driven due to payer structure and reimbursement dynamics.
• International uptake is typically slower without major local payer incentives and dermatology channel infrastructure.

Implication

• Revenue sensitivity is high to U.S. formulary status and exclusivity.

Key financial sensitivities for FINACEA if generic substitution accelerates

Metrics that usually move first

• New prescriptions and refill persistence rate.
• Net price via rebate and contracting changes.
• Average sales per pharmacy, reflecting tier and coverage changes.

Revenue-line effects

• Once generic competition starts, branded sales typically do not recover meaningfully without a strong contracting response or evidence of superior patient adherence.

Timeline view: how exclusivity and entry typically map to earnings

Typical revenue pattern for branded topical acne drugs

• Pre-loss period: stable but payer-constrained growth; increases mostly from formulary access and physician adoption.
• Loss window: earnings volatility increases as generic launch timelines become clearer.
• Post-entry: rapid share erosion; branded revenue tends to decline toward generic-driven market clearing price.

Key Takeaways

• FINACEA’s market dynamics are dominated by payer tiering, vehicle-driven adherence, and price pressure from generics and low-cost topical acne standards.
• Financial trajectory for a branded topical acne drug is highly sensitive to exclusivity expiration, Orange Book patent posture, and the timeline of any ANDA paragraph IV activity and settlement outcomes.
• Formulation and vehicle-specific IP can slow substitution, but once enforceable barriers clear, topical brands typically experience sharp early sales declines driven by pharmacy switching and net price compression.
• The primary levers supporting continued branded performance are formulary placement, rebate strategy, and persistence via patient tolerability and ease of use.

FAQs

1) What market forces most strongly influence FINACEA prescription volume?
Formulary tier placement, net price after rebates, and prescriber adoption in dermatology versus primary care.

2) How do foam vehicle characteristics affect competitive substitution?
Foam performance consistency and tolerability equivalence can slow generic switching if formulation or manufacturing specs are difficult to replicate.

3) What financial metric best predicts FINACEA earnings resilience in late-cycle?
Net sales per pharmacy (reflecting coverage and tier status) and refill persistence, because these tighten first under payer pressure.

4) Can patent settlements delay FINACEA generic entry even after Paragraph IV filings?
Yes; settlements can delay launch and protect branded cash flows for the settlement period, depending on terms and statutory stays.

5) Are biosimilar dynamics relevant to FINACEA?
No. FINACEA is not a biologic product.

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (U.S. FDA). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA Orange Book Instructions and Patent/Exclusivity guidance. (U.S. FDA). https://www.fda.gov/
3. FDA Guidance for Industry: Patent Listing and Orange Book reporting. (U.S. FDA). https://www.fda.gov/
4. Hatch-Waxman Act framework summaries and ANDA patent certification concepts (30-month stay, paragraph IV). (U.S. FDA / statutory resources). https://www.fda.gov/

DrugChatter Q&A for FINACEA

Can Finacea be used for rosacea pustules?